Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratios.
Cancer Biother Radiopharm
; 17(3): 307-16, 2002 Jun.
Article
em En
| MEDLINE
| ID: mdl-12136523
ABSTRACT
Optimal tumor imaging using radiolabeled antibodies (Abs) depends on obtaining the highest possible tumor/non-tumor localization ratios. To increase this ratio, in a mouse xenograft model system, we induced rapid blood clearance of the Ab after extensive penetration of a solid tumor, at 24 hr after Ab injection. By using galactosylated streptavidin (gal-SA) as a clearing agent for biotinylated Abs, and by using an 111In-DTPA (diethylenetriaminepentaacetic acid) label, clearance was directed to hepatocytes (as opposed to Kupffer cells), and the radiolabel was excreted by the hepatocytes into bile, thereby reducing accumulation in the liver. In this study, we directly compared this approach with the use of 99mTc-F(ab)2 fragments, using the same Ab to carcinoembryonic antigen (CEA), with a colon carcinoma xenograft. The gal-SA clearance method produced substantially higher tumor/non-tumor localization ratios for all tissues except the liver, and even for the liver the disadvantage of the gal-SA clearance method was small. We also tested the gal-SA clearance method with a xenograft model of human B-cell lymphoma, using anti-CD22. High tumor/non-tumor ratios were obtained, as previously described with carcinomas of the lung and colon. Therefore, this approach appears to be a generally applicable strategy to obtain relatively high tumor/non-tumor ratios.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Radioisótopos de Índio
/
Moléculas de Adesão Celular
/
Linfoma de Células B
/
Neoplasias do Colo
/
Estreptavidina
/
Anticorpos Monoclonais
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2002
Tipo de documento:
Article